胶质瘤超全切除术的系统综述
该系统综述检索EMBASE、MEDLINE、Scopus和Web of Science数据库,最终纳入7项研究、共492例患者(其中88例接受超全切除术),证据多为牛津循证医学中心4级。初步低质量证据支持超全切除术可提高低级别和高级别胶质瘤的总生存期与无进展生存期。
要点
- 共492例患者中88例行超全切除术,高级别胶质瘤51例、低级别37例。
- 初步低质量证据支持超全切除术提高低级别和高级别胶质瘤的总生存期与无进展生存期。
- 证据不足以无条件应用超全切除术,尤其低级别胶质瘤术后神经功能缺损可致长期残疾。
核心结论
- 文献提示证据不足以无条件应用超全切除术,尤其低级别胶质瘤术后神经功能缺损可致长期残疾。
- 初步研究报告无进展生存期和总生存期增加,但需在更大患者人群、结局指标明确的前瞻性研究中验证以减少偏倚。
研究设计与样本
- 系统综述,检索EMBASE、MEDLINE、Scopus和Web of Science数据库。
- 排除病例研究、综述或社论、非英文、仅摘要、脑转移瘤及描述性研究,其余纳入。
- 309篇唯一文献经全文审查41项研究,最终纳入7项分析,多为牛津循证医学中心4级证据。
- 合并队列共492例患者(男214例、女278例,年龄18至82岁),其中88例行超全切除术。
- 未检索到随机对照试验。
主要发现
- 88例行超全切除术,其中高级别胶质瘤51例、低级别胶质瘤37例。
- 主要测量结局为卡氏功能状态评分、总生存期、无进展生存期、术后神经功能缺损及间变性转化。
- 初步低质量证据支持超全切除术提高低级别和高级别胶质瘤的总生存期与无进展生存期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 证据多为牛津循证医学中心4级质量。
- 未检索到随机对照试验。
- 初步研究仅包含少数中心的数据。
- 相关主张需在更大患者人群、结局指标明确的前瞻性研究中验证以减少潜在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emerging evidence suggests survival benefit from resection beyond all MRI abnormalities present on T1-enhanced and T2‒fluid attenuated inversion recovery (FLAIR) modalities in glioma (supratotal resection); however, the quality of evidence is unclear. We addressed this question via systematic review of the literature. METHODS: EMBASE, MEDLINE, Scopus, and Web of Science databases were queried. Case studies, reviews or editorials, non-English, abstract-only, brain metastases, and descriptive works were excluded. All others were included. RESULTS: Three hundred and nine unique references yielded 41 studies for full-text review, with 7 included in the final analysis. Studies were mostly of Oxford Center for Evidence-Based Medicine Level 4 quality. A total of 88 patients underwent supratotal resection in a combined cohort of 492 patients (214 males and 278 females, age 18 to 82 years). Fifty-one supratotal resections were conducted on high-grade gliomas, and 37 on low-grade gliomas. Karnofsky performance status, overall survival, progression-free survival, neurological deficits postoperatively, and anaplastic transformation were the main measured outcomes. No randomized controlled trials were identified. Preliminary low-quality support was found for supratotal resection in increasing overall survival and progression-free survival for both low-grade and high-grade glioma. CONCLUSION: The literature suggests insufficient evidence for carte blanche application of supratotal resection, particularly in lower-grade gliomas where neurological deficits can result in long-term disability. While the preliminary studies discussed here, containing data from only a few centers, have reported increased progression-free and overall survival, these claims require validation in prospective research studies involving larger patient populations with clearly defined appropriate outcome metrics in order to reduce potential bias.
引用
- de Leeuw CN, Vogelbaum MA. Supratotal resection in glioma: a systematic review. Neuro Oncol. 2019. PMID: 30321384. doi:10.1093/neuonc/noy166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。